Semaglutide
Semaglutide is a GLP-1 receptor agonist available in multiple prescription products.
BY GOAL
Weight Loss
Metabolic pathways and the evidence behind weight-management research
RESEARCH TOPIC
Weight Loss
Metabolic pathways and the evidence behind weight-management research
Association with this topic does not establish clinical benefit. Read the limitations and product-specific US status in each profile
Tirzepatide
Tirzepatide is a prescription peptide that activates two incretin receptors, GIP and GLP-1.
Retatrutide
Retatrutide is an investigational peptide designed to activate GIP, GLP-1, and glucagon receptors.
Cagrilintide
Cagrilintide is a long-acting amylin analog studied for weight management, including in combination with semaglutide.
Liraglutide
Liraglutide is a prescription GLP-1 receptor agonist used in distinct products for diabetes and weight management.
Mazdutide
Mazdutide is a dual GLP-1 and glucagon receptor agonist studied for obesity and metabolic disease.
Survodutide
Survodutide is an investigational dual glucagon and GLP-1 receptor agonist.
AOD-9604
AOD-9604 is a modified fragment related to the C-terminal region of human growth hormone.
Tesofensine
Tesofensine is an investigational monoamine reuptake inhibitor, not a peptide.
Before drawing a conclusion
A proposed mechanism, a laboratory finding, and a patient outcome answer different questions. Read the study population and design before applying a result to a new setting
How to read the evidence ↗